These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19084393)

  • 1. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
    Kweekel DM; Gelderblom H; Antonini NF; Van der Straaten T; Nortier JW; Punt CJ; Guchelaar HJ
    Eur J Cancer; 2009 Mar; 45(4):572-8. PubMed ID: 19084393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.
    Kweekel DM; Koopman M; Antonini NF; Van der Straaten T; Nortier JW; Gelderblom H; Punt CJ; Guchelaar HJ
    Br J Cancer; 2008 Oct; 99(8):1316-21. PubMed ID: 18797455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy.
    Kanai M; Yoshioka A; Tanaka S; Nagayama S; Matsumoto S; Nishimura T; Niimi M; Teramukai S; Takahashi R; Mori Y; Kitano T; Ishiguro H; Yanagihara K; Chiba T; Fukushima M; Matsuda F
    Cancer Epidemiol; 2010 Apr; 34(2):189-93. PubMed ID: 20308030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients.
    Jun L; Haiping Z; Beibei Y
    Swiss Med Wkly; 2009 Dec; 139(49-50):724-8. PubMed ID: 20047135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
    Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ;
    J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.
    Knijn N; Tol J; Koopman M; Werter MJ; Imholz AL; Valster FA; Mol L; Vincent AD; Teerenstra S; Punt CJ
    Eur J Cancer; 2011 Feb; 47(3):369-74. PubMed ID: 21067912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH; Hua D; Du X
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
    Zarate R; Rodríguez J; Bandres E; Patiño-Garcia A; Ponz-Sarvise M; Viudez A; Ramirez N; Bitarte N; Chopitea A; Gacía-Foncillas J
    Br J Cancer; 2010 Mar; 102(6):987-94. PubMed ID: 20216541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome.
    Le Morvan V; Smith D; Laurand A; Brouste V; Bellott R; Soubeyran I; Mathoulin-Pelissier S; Robert J
    Pharmacogenomics; 2007 Dec; 8(12):1693-703. PubMed ID: 18085999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy.
    Lecomte T; Landi B; Beaune P; Laurent-Puig P; Loriot MA
    Clin Cancer Res; 2006 May; 12(10):3050-6. PubMed ID: 16707601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
    Chen YC; Tzeng CH; Chen PM; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
    Cancer Sci; 2010 Feb; 101(2):530-5. PubMed ID: 19922504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
    Ruzzo A; Graziano F; Loupakis F; Rulli E; Canestrari E; Santini D; Catalano V; Ficarelli R; Maltese P; Bisonni R; Masi G; Schiavon G; Giordani P; Giustini L; Falcone A; Tonini G; Silva R; Mattioli R; Floriani I; Magnani M
    J Clin Oncol; 2007 Apr; 25(10):1247-54. PubMed ID: 17401013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.
    Ye F; Liu Z; Tan A; Liao M; Mo Z; Yang X
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):733-40. PubMed ID: 23299794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association analysis of glutathione-S-transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M-VAC chemotherapy.
    Yokomizo A; Yamamoto K; Kinukawa N; Tsunoda T; Koga H; Naito S
    Int J Urol; 2007 Jun; 14(6):500-4. PubMed ID: 17593093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy.
    Funke S; Timofeeva M; Risch A; Hoffmeister M; Stegmaier C; Seiler CM; Brenner H; Chang-Claude J
    Pharmacogenomics; 2010 Jan; 11(1):33-41. PubMed ID: 20017670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer.
    Stoehlmacher J; Park DJ; Zhang W; Groshen S; Tsao-Wei DD; Yu MC; Lenz HJ
    J Natl Cancer Inst; 2002 Jun; 94(12):936-42. PubMed ID: 12072547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
    Kim JG; Chae YS; Sohn SK; Moon JH; Ryoo HM; Bae SH; Kum Y; Jeon SW; Lim KH; Kang BM; Park IJ; Choi GS; Jun SH
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):953-60. PubMed ID: 19219602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
    Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
    Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.
    Chen XF; Wang R; Yin YM; Røe OD; Li J; Zhu LJ; Guo RH; Wu T; Shu YQ
    Biomed Pharmacother; 2012 Jun; 66(4):279-84. PubMed ID: 22397758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
    Argyriou AA; Cavaletti G; Antonacopoulou A; Genazzani AA; Briani C; Bruna J; Terrazzino S; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Psaromyalou A; Angelopoulou A; Kalofonos HP
    Cancer; 2013 Oct; 119(19):3570-7. PubMed ID: 23821303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.